UBS Downgrades Acadia Pharmaceuticals to Neutral, Lowers Price Target to $23
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsDowngradesPrice Target
UBS analyst Ashwani Verma downgrades Acadia Pharmaceuticals (NASDAQ:ACAD) from Buy to Neutral and lowers the price target from $49 to $23.
UBS analyst Ashwani Verma downgrades Acadia Pharmaceuticals (NASDAQ:ACAD) from Buy to Neutral and lowers the price target from $49 to $23.